antivir
drug
drug
design
tradit
focus
inhibit
key
protein
essenti
success
viral
replic
approach
seen
nucleosid
nucleotid
analog
inhibitor
herpesviru
dna
polymeras
human
immunodefici
viru
hiv
revers
transcriptas
inhibitor
hiv
proteas
inhibitor
influenza
hemagglutinin
inhibitor
de
clercq
kinchington
redshaw
haffey
field
field
appar
approach
result
parad
clinic
effect
drug
best
exampl
success
stori
acyclovir
acv
use
therapeut
prophylact
inhibit
acut
herp
simplex
viru
hsv
lesion
format
durat
zidovudin
azt
approach
promis
newer
antivir
drug
may
limit
present
approach
limit
best
illustr
concern
emerg
clinic
import
drugresist
viru
mutant
problem
review
herpesvirus
hiv
field
biron
de
clercq
bowen
et
ul
herpesvirus
problem
appar
immunocompromis
host
treat
suboptim
drug
dose
hiv
antivir
one
drug
treatment
result
total
viral
suppress
rapid
resist
develop
vari
drug
drug
result
lack
potent
sustain
viru
suppress
attent
turn
combin
therapi
clinic
thu
avail
potent
divers
group
inhibitor
one
infecti
agent
provid
richer
armamentarium
choos
effect
combin
one
discov
novel
antivir
inhibitor
one
approach
modif
known
inhibitor
enzym
substrat
set
structureact
relationship
sar
studi
choos
inhibitor
attract
select
index
ratio
concentr
antivir
efficaci
compar
toxic
approach
produc
array
nucleosid
nucleotid
inhibitor
hsv
dna
polymeras
hiv
revers
transcriptas
hiv
proteas
substrat
analog
inhibitor
absenc
defin
enzym
substrat
tradit
approach
employ
highvolum
screen
evalu
thousand
compound
lead
specif
action
identifi
lead
sar
refin
fruit
approach
entrench
approach
pharmaceut
modu
operundi
miss
great
opportun
design
inhibitor
gene
target
provid
viru
herp
simplex
viru
open
read
frame
function
mani
result
protein
still
poorli
defin
human
immunodefici
viru
nine
open
read
frame
yet
revers
transcriptas
proteas
effect
address
antivir
target
tradit
approach
human
cytomegaloviru
hcmv
open
read
frame
provid
rich
hunt
ground
search
effect
antivir
mean
identifi
inhibitor
one
new
approach
recogn
versatil
practic
identifi
develop
antivir
drug
approach
use
antisens
nucleic
acid
complementari
viral
rna
block
mrna
translat
genom
replic
take
form
antisens
oligonucleotid
appli
infect
cell
antisens
rna
express
within
cell
ribozym
capabl
complementari
bind
target
rna
target
cleavag
via
inher
catalyt
activ
chapter
summar
opportun
use
approach
identifi
novel
antivir
drug
target
develop
novel
antivir
strategi
approach
embodi
emerg
field
genet
pharmacolog
develop
drug
gene
therapi
control
gene
express
field
goodchild
yu
et
al
temsamani
agraw
review
genet
pharmacolog
relat
antivir
antisens
research
drug
develop
major
research
emphasi
focus
identif
oligonucleotid
antivir
agent
principl
suggest
sequenc
viral
rna
genom
rna
mrna
known
one
abl
design
complementari
oligonucleotid
hybrid
inhibit
function
replic
genom
mrna
fig
principl
first
document
observ
zamecnik
stephenson
use
phosphodiest
oligodeoxynucleotid
block
rou
sarcoma
viru
replic
stephenson
zamecnik
road
principl
initi
observ
practic
antivir
util
long
one
learn
choos
prefer
viral
rna
target
sequenc
maximum
antisens
impact
figur
mechan
antisens
oligonucleotid
inhibit
antisens
oligonucleotid
bind
rarget
rna
cell
prevent
protein
product
directli
translat
arrest
addit
dnarna
hybrid
form
oligonucleotid
bind
rna
recogn
rnase
h
digest
rna
portion
hybrid
destroy
mrna
free
oligonucleotid
bind
anoth
mrna
molecul
chemic
alter
antisens
oligonucleotid
enhanc
stabil
optim
activ
biolog
system
recogn
array
biolog
action
oligonucleotid
may
contribut
antivir
activ
also
toxic
antivir
antisens
oligonucleotid
display
high
degre
specif
reflect
uniqu
nucleotid
sequenc
provid
genet
code
exact
complementari
base
pair
target
rna
result
introduc
mismatch
nucleotid
interfer
hybrid
oligonucleotid
rna
target
substitut
inappropri
sequenc
ccscrambl
order
nucleotid
revers
predict
antisens
orient
reduc
antivir
activ
furthermor
antisens
mechan
predict
select
inhibit
gene
express
suggest
guidelin
accept
oligonucleotid
activ
fit
criteria
present
stein
krieg
direct
demonstr
antisens
oligonucleotid
bind
target
rna
violat
biolog
role
within
cell
gener
difficult
obtain
although
numer
indirect
line
evid
suggest
exampl
studi
antisens
oligonucleotid
cytomegaloviru
show
select
gene
target
inhibit
result
potent
antivir
activ
pari
et
al
addit
recent
studi
antisens
mechan
fruit
demonstr
direct
antisens
activ
situ
politz
et
al
gile
et
al
b
detail
observ
relat
antivir
activ
describ
section
antisens
oligonucleotid
highli
select
compound
virtu
interact
specif
segment
rna
potenti
antivir
identif
appropri
target
rna
sequenc
antisens
oligonucleotid
perform
two
level
optim
gene
within
viru
optim
sequenc
within
rna
optim
gene
gene
essenti
viru
replic
andor
essenti
virul
thu
wide
varieti
target
may
avail
antisens
approach
valid
target
discoveri
effect
inhibitor
attain
simultan
valid
discoveri
process
illustr
studi
hcmv
discuss
sure
oligonucleotid
design
target
express
structur
gene
hiv
lisziewicz
et
al
anazodo
et
al
hepat
b
viru
hbv
korba
gerin
regulatori
gene
hiv
matsukura
et
al
hcmv
h
et
al
pariet
epsteinbarr
viru
ebv
roth
etal
daibata
et
al
human
papillomaviru
hpv
cowsert
et
al
varieti
function
hbv
wu
wu
offensperg
et
al
korba
gerin
studi
set
compar
viral
target
vulner
antisens
inhibit
fewer
done
also
control
nonantisens
antivir
effect
hiv
oligonucleotid
target
regulatori
gene
rev
viral
enzym
pol
structur
gene
gag
compar
singl
studi
kinchington
et
oligonucleotid
report
equal
activ
acut
infect
assay
rev
target
oligonucleotid
oligonucleotid
activ
chronic
infect
cell
suggest
optim
gene
antisens
target
howev
sequenc
gene
evalu
inhibit
requir
pm
concentr
clear
optim
sequenc
actual
chosen
exampl
gem
phosphorothio
oligonucleotid
target
gag
gene
found
activ
submicromolar
concentr
acut
infect
assay
longterm
model
system
agraw
tang
lisziewicz
et
al
hbv
rna
sequenc
identifi
essenti
initi
revers
transcript
packag
viral
rna
pollack
ganem
oligonucleotid
region
report
potent
inhibitor
hbv
replic
korba
gerin
rna
virus
addit
genet
target
may
also
provid
sinc
genom
posit
picornavirus
neg
influenza
doublestrand
reovirus
well
individu
transcript
avail
instanc
target
oligonucleotid
genom
strand
respiratori
syncyti
viru
inhibit
rna
replic
previous
shown
replic
influenza
viru
vesicular
stomat
viru
inhibit
oligonucleotid
target
genom
rna
lemaitr
et
al
leiter
et
al
clear
defin
rule
identifi
optim
antisens
gene
target
viru
versatil
design
antisens
inhibitor
heretofor
unassail
target
provid
great
opportun
eventu
clarifi
rule
much
effort
also
made
identifi
correct
rna
target
sequenc
within
gene
clear
rule
easili
predict
sequenc
access
oligonucleotid
comput
model
rna
secondari
structur
sczakiel
etal
well
oligonucleotid
hybrid
effici
stull
et
al
frequenc
han
et
al
compar
antisens
oligonucleotid
activ
antisens
activ
shown
correl
well
hybrid
strength
howev
rna
secondari
structur
predict
antisens
activ
often
vitro
translat
inhibit
use
screen
seri
potenti
oligonucleotid
inhibitor
activ
oligonucleotid
evalu
cellular
andor
antivir
assay
chen
et
al
laboratori
oligonucleotid
librari
screen
bind
target
rna
vitro
assay
describ
frank
et
al
frank
goodchild
frank
et
al
modifi
ho
et
al
bind
measur
rnase
h
cleavag
rnaoligonucleotid
hybrid
sensit
site
map
specif
oligonucleotid
synthes
evalu
cellular
assay
exampl
techniqu
shown
fig
correl
exist
access
rna
region
vitro
cell
although
one
would
expect
site
identifi
use
vitro
techniqu
purifi
rna
target
would
expect
situ
target
rna
may
carri
numer
bind
protein
previous
mention
fundament
mission
antisens
oligonucleotid
hybrid
viral
rna
target
inhibit
function
inhibit
may
facilit
cleav
target
rna
rnase
h
recogn
rnaoligodeoxynucleotid
complex
inhibit
rna
translat
splice
hybrid
arrest
end
result
figur
antisens
oligonucleotid
select
oligonucleotid
librari
thin
line
incub
endlabel
rna
thick
line
treat
rnase
h
rna
region
bound
oligonucleotid
digest
produc
famili
shorter
label
rna
separ
polyacrylamid
gel
discret
famili
rna
detect
gel
lane
rh
compar
molecular
weight
marker
lane
mw
identifi
region
maximum
oligonucleotid
bind
either
direct
inhibit
target
rna
genom
replic
rna
viru
inhibit
translat
target
mrna
principl
unmodifi
oligodeoxynucleotid
could
satisfi
mission
practic
chemic
modif
oligonucleotid
necessari
robust
antisens
efficaci
modif
design
enhanc
stabil
retain
capac
hybrid
target
rna
recruit
rnase
h
addit
chemic
modif
use
alter
hydrophob
hydrophil
thu
alter
present
oligonucleotid
infect
cell
function
group
phosphat
hydroxyl
residu
natur
nucleic
acid
modifi
indic
fig
gener
modif
jeopard
capac
oligonucleotid
particip
watsoncrick
base
pair
avoid
modif
focus
phosphodiest
backbon
andor
sugar
moieti
loss
neg
charg
greater
hydrophob
cost
loss
rnase
h
activ
altern
replac
hydrogen
posit
deoxyribos
hydroxymethyl
group
sugar
becom
modifi
ribos
hybrid
strongli
complementari
mrna
ribonucleotid
provid
greater
stabil
duplex
indic
elev
chang
demonstr
fig
allow
one
synthes
tailor
oligonucleotid
balanc
characterist
hybrid
affin
hydrophob
capac
recruit
rnase
hmediat
cleavag
target
rna
import
oligonucleotid
modif
design
effect
drug
evalu
anim
model
system
clinic
first
gener
wide
use
antisens
oligonucleotid
ps
compound
bodi
data
biodistribut
pharmacokinet
metabol
anim
human
avail
studi
summar
agraw
temsamani
field
goodchild
crook
bennett
second
gener
antisens
oligonucleotid
emerg
includ
combin
nucleotid
modif
within
oligonucleotid
instanc
hybrid
oligonucleotid
may
defin
substitut
andor
end
ribonucleosid
maintain
phosphorothio
backbon
chimer
oligonucleotid
may
defin
substitut
andor
end
nonion
internucleotid
linkag
selfstabil
oligonucleotid
may
defin
phophorothio
phosphodiest
two
domainsa
singlestrand
antisens
sequenc
hairpin
loop
end
pharmacolog
characterist
modif
summar
paper
agraw
temsamani
clear
ongo
studi
one
design
antisens
inhibitor
potenti
high
select
target
inhibit
one
chemic
modifi
select
oligonucleotid
tailor
eventu
drug
enhanc
stabil
perhap
tissuespecif
uptak
metabol
addit
first
observ
oral
uptak
tissu
distribut
hybrid
oligonucleotid
zhang
et
al
indic
opportun
develop
oligonucleotid
therapeut
oral
bioavail
may
hand
date
antivir
cell
cultur
studi
anim
efficaci
clinic
studi
employ
ps
oligonucleotid
recent
hybridon
cambridg
introduc
first
advanc
oligonucleotid
gem
hybrid
oligonucleotid
clinic
studi
see
section
b
studi
use
ps
oligonucleotid
gener
use
inform
concern
antisens
activ
appar
ps
compound
may
also
addit
nonantisens
mode
antivir
activ
readili
demonstr
hsv
ebv
hiv
gao
et
af
yao
et
al
wyatt
et
af
ojwang
et
af
ojwang
et
af
buckheit
et
af
nonantisens
mechan
includ
inhibit
viru
bind
intern
buckheit
et
af
inhibit
virusspecif
dna
polymeras
yao
et
af
gao
et
af
gao
et
af
effect
relat
gener
polyanion
natur
oligonucleotid
pronounc
specif
sequenc
exampl
oligonucleotid
contain
four
consecut
g
residu
form
tetramer
structur
potent
inhibit
absorpt
hiv
hsv
buckheit
et
af
oligonucleotid
contain
g
residu
inhibit
absorpt
integr
hiv
ojwang
et
af
believ
due
higher
order
structur
oligonucleotid
certain
oligonucleotid
contain
cpg
motif
may
also
stimul
b
cell
prolifer
immunostimulatori
characterist
krieg
et
af
nonantisens
effect
may
contribut
significantli
antivir
effect
oligonucleotid
enhanc
activ
cell
cultur
unfortun
effect
might
certain
case
mask
antisens
effect
make
ration
select
gene
target
sequenc
target
difficult
anomali
fulli
discuss
context
individu
antivir
studi
far
antivir
studi
use
oligonucleotid
cell
cultur
evalu
neglect
appli
rigor
definit
antisens
inhibit
howev
field
matur
criteria
antisens
antivir
oligonucleotid
becom
precis
antisens
mechan
antivir
activ
repeatedli
confirm
studi
report
emphas
studi
clear
definit
antisens
mechan
antivir
activ
thu
literatur
survey
focus
key
studi
illustr
field
evolv
novelti
key
studi
help
build
understand
role
oligonucleotid
antivir
agent
correctli
phrase
john
coffin
group
infecti
agent
receiv
much
attent
scientist
recent
year
retrovirus
coffin
group
capac
replic
product
cytolyt
infect
becom
latent
genet
inform
insert
host
genet
materi
capac
captur
alter
host
genet
inform
form
oncogen
readili
mutabl
thu
readili
escap
antivir
effect
mani
initi
effect
inhibitor
associ
wide
varieti
diseas
includ
benign
malign
tumor
acquir
immunodefici
syndrom
aid
result
also
favorit
target
antivir
studi
includ
antisens
studi
first
detail
observ
inhibit
viru
replic
oligonucleotid
design
antisens
publish
stephenson
zamecnik
use
unmodifi
block
termini
isourea
deriv
oligonucleotid
sequenc
complementari
reiter
repeat
virion
rna
block
viru
replic
p
measur
appear
rou
sarcoma
viru
revers
transcriptas
furthermor
use
vitro
translat
system
author
demonstr
select
inhibit
viral
rna
translat
sequenc
specif
inhibit
sinc
earli
observ
abund
antisens
paper
concern
anim
human
retrovirus
appear
bovin
leukemia
viru
encod
transactiv
protein
tax
promot
viral
transcript
activ
cellular
gene
associ
tumorogenesi
cantor
palmer
evalu
capac
unmodifi
inhibit
tax
translat
tax
messag
rabbit
reticulocyt
lysat
cantor
palmer
appar
sequencespecif
inhibit
translat
observ
oligonucleotid
direct
portion
tax
rna
includ
aug
one
oligonucleotid
contain
fourg
sequenc
target
sequenc
actual
stimulatori
translat
undefin
mechan
research
extend
kitajima
et
al
demonstr
murin
cell
cultur
implant
taxproduc
fibrosarcoma
cell
modifi
phosphorothio
substitut
termin
three
nucleotid
end
inhibit
tax
protein
express
kitajima
et
al
b
greater
inhibit
tax
express
matur
tumor
occur
intraperiton
inject
pgg
similarli
modifi
sens
control
oligonucleotid
ineffect
curious
taxexpress
cell
uptak
oligonucleotid
sevenfold
higher
nontaxexpress
cell
uptak
appear
receptor
mediat
tax
protein
caus
transcript
transactiv
implic
human
cell
leukemia
viru
type
htlvi
mediat
leukemogenesi
perhap
activ
elev
express
nfkb
kitajima
also
report
antisens
oligonucleotid
complementari
sens
strand
target
nfkb
mrna
translat
start
site
inhibit
taxtransform
fibroblast
growth
htlvitransform
human
lymphocyt
growth
mice
antisens
nfkb
caus
rapid
regress
taxtransform
tumor
kitajima
et
al
studi
also
suggest
although
tax
necessari
transform
htlviinfect
cell
mainten
high
level
nfkb
import
sustain
malign
phenotyp
sinc
identif
sequenc
hiv
strong
interest
identifi
potent
oligonucleotid
inhibitor
would
potenti
develop
therapi
aid
zamecnik
et
al
goodchild
et
al
describ
inhibit
hiv
replic
synthet
oligonucleotid
phosphorothio
oligonucleotid
gem
design
agraw
tang
bind
gag
region
hiv
rna
identifi
therapeut
develop
agraw
tang
gem
select
potent
antivir
effect
design
bind
wellconserv
region
viral
genom
clinic
isol
illustr
one
advantag
antivir
design
antisenseth
potenti
select
among
array
molecular
target
inhibit
studi
agraw
et
al
oligonucleotid
evalu
capac
inhibit
viru
replic
longterm
infect
cell
cultur
select
antisens
sequenc
compar
unrel
random
sequenc
oligonucleotid
result
suggest
select
antisens
sequenc
consider
advantag
efficaci
matsukura
colleagu
also
evalu
inhibit
hiv
replic
ps
oligonucleotid
case
target
hiv
rev
rna
matsukura
et
al
report
sequenc
specif
antivir
effect
lack
activ
sens
random
homopolymer
sequenc
expect
effect
hiv
mrna
profil
treatment
basi
potent
antivir
activ
gem
hiv
cell
cultur
infect
studi
wellconserv
target
sequenc
phase
h
clinic
evalu
intraven
therapi
h
n
begun
unit
state
franc
martin
us
french
gem
collabor
studi
group
serini
et
al
us
trial
random
doubleblind
placebocontrol
doseescal
studi
use
gem
intraven
continu
infus
week
french
studi
gem
given
infus
everi
day
day
studi
entrant
must
viral
burden
copi
viral
rnaml
plasma
date
safeti
demonstr
dose
mgkg
continu
infus
mgkg
repeat
intermitt
infus
initi
pharmacokinet
phase
singl
dose
studi
use
gem
plasma
disappear
radioact
associ
gem
sum
two
exponenti
mean
halfliv
hr
intact
degrad
materi
found
plasma
elimin
mainli
urinari
excret
primarili
lower
molecular
weight
metabolit
maximum
toler
dose
yet
achiev
zhang
et
al
anazodo
et
al
demonstr
partial
phosphorothio
target
wellconserv
code
region
gag
gene
inhibit
express
mrna
viral
precursor
protein
pss
protein
cleavag
product
co
cell
stabli
transfect
plasmid
contain
gagpol
region
fig
system
use
lipofectin
oligonucleotid
enhanc
activ
invers
sequenc
doubl
mismatch
control
oligonucleotid
less
effect
pm
antisens
inhibit
viral
replic
measur
revers
transcriptas
level
sequencespecif
manner
without
inhibit
cell
protein
biosynthesi
larg
subunit
ribonucleotid
reductas
cell
growth
rate
oligonucleotid
antivir
studi
mention
previous
antiretrovir
effect
oligonucleotid
nonantisens
mechan
ampli
demonstr
matsukura
et
al
demonstr
phosphorothio
homopolym
dc
potent
inhibitor
hiv
infect
matsukura
et
al
direct
potent
k
valu
nm
inhibit
revers
transcriptas
rt
rnase
h
primer
extens
function
also
demonstr
hiv
hatta
et
al
bordier
et
al
austermann
et
al
avian
myeloblastosi
viru
hatta
et
al
boiziau
et
al
addit
inhibit
rt
other
demonstr
inhibit
hiv
adsorpt
cell
zelphati
et
al
recent
interest
phosphorothio
oligonucleotid
sequenc
identifi
potent
inhibitor
hiv
viral
envelop
protein
bind
cell
receptor
specif
well
nonantisens
oligonucleotid
hiv
inhibitor
phosphorothio
dc
bind
loop
stein
et
al
breadth
antihiv
mechan
oligonucleotid
expand
demonstr
figur
inhibit
hiv
product
cell
stabli
transfect
express
treat
antisens
oligonucleotid
span
base
hiv
two
control
oligonucleotid
contain
either
two
mutat
invers
sequenc
control
also
test
product
measur
immunoprecipit
use
rabbit
polyclon
antibodi
decreas
cell
treat
antisens
oligonucleotid
control
oligonucleotid
alter
level
cell
transfect
express
anazodo
et
al
compos
deoxyguanosin
thymidin
singl
phosphorothio
internucleotid
linkag
end
potent
inhibitor
hiv
integras
compound
relat
compound
ojwang
et
form
tetram
owe
part
motif
g
sequenc
appear
enhanc
oligonucleotid
capac
block
viru
adsorpt
bishop
et
al
observ
emphas
import
defin
mechan
action
given
oligonucleotid
prior
identifi
antisens
oligonucleotid
howev
fact
oligonucleotid
may
contribut
numer
mechan
toward
antivir
activ
addit
antisens
mechan
may
case
asset
pursuit
clinic
use
antivir
drug
herp
simplex
viru
type
respons
acut
infect
cold
sore
herp
genitali
herp
enceph
may
result
persist
latent
infect
neuron
sensori
ganglia
may
punctuat
acut
recurr
roizman
sear
herp
simplex
viru
replic
like
herpesvirus
result
coordin
regul
sequenti
order
cascad
transcript
translat
event
broadli
categor
immedi
earli
earli
late
event
roizman
sear
immedi
earli
gene
transcrib
without
requir
previou
viral
protein
synthesi
includ
transactiv
gene
product
icp
earli
gene
includ
mani
requir
viral
dna
synthesi
includ
dna
polymeras
transcrib
immedi
earli
gene
translat
initi
final
late
gene
transcript
initi
follow
viral
dna
synthesi
includ
structur
protein
virion
capsid
protein
gene
ul
ul
vmw
vmw
also
known
vp
atif
identifi
essenti
structur
element
virion
also
transactiv
immedi
earli
gene
express
roizman
sear
although
simplist
descript
event
replic
cycl
serv
illustr
multipl
antivir
target
potenti
avail
truncat
replic
variou
stage
draper
et
al
report
inhibit
transactiv
icp
promot
viru
replic
unmodifi
oligodeoxynucleotid
target
put
translat
initi
site
vmw
draper
et
al
sequenc
specif
activ
suggest
rel
activ
two
differ
although
rigor
studi
demonstr
specif
antisens
effect
perform
inhibit
studi
use
vmw
target
perform
kmetz
et
al
use
oligonucleotid
ps
compound
kmetz
et
al
investig
found
p
concentr
oligonucleotid
reduc
replic
strain
ko
greater
inhibit
correl
well
reduct
vmw
protein
random
serv
control
minim
inhibitori
activ
extens
nucleotid
end
result
potent
inhibitor
studi
suggest
specif
target
effect
inhibit
vmw
result
reduc
infect
sequenc
specif
random
less
activ
thu
potenti
antisens
mechan
action
seri
studi
john
hopkin
group
kulka
et
kulka
et
al
kulka
et
al
kean
et
al
investig
antisens
oligonucleotid
target
splice
donoracceptor
site
immedi
earli
premrna
ie
icp
protein
earlier
studi
investig
use
methyl
phosphon
oligodeoxynucleotid
report
sequenc
specif
inhibit
viru
replic
methyl
phosphon
target
ie
mrna
splice
donor
site
effect
reduc
viru
growth
pm
wherea
oligonucleotid
central
two
residu
invert
inact
methyl
phosphon
reduc
viru
yield
local
treatment
mous
ear
infect
kulka
et
al
although
studi
suggest
specif
activ
effect
concentr
make
impract
potenti
therapeut
drug
recent
group
found
use
methyl
phosphon
target
introdexon
junction
splice
acceptor
substitut
dt
greater
affin
rna
target
fivefold
reduct
inhibitori
concentr
icso
pm
versu
inhibit
achiev
sequenc
specif
oligonucleotid
indic
rel
lack
activ
mismatch
oligonucleotid
kean
et
al
ul
late
gene
encod
protein
kinas
appear
virion
structur
protein
ps
oligonucleotid
target
translat
initi
codon
potent
inhibitor
viru
replic
icso
valu
p
crook
et
al
activ
quit
potent
demonstr
characterist
sequenc
specif
gene
target
select
must
follow
label
antivir
activ
antisens
poddevin
et
al
investig
seri
phosphodiest
oligonucleotid
region
complementari
target
ie
premrna
noncomplementari
flank
sequenc
form
hairpin
structur
similar
selfstabil
phosphorothio
oligonucleotid
describ
previous
studi
well
control
nonsequencedepend
antivir
effect
demonstr
ad
stabil
degrad
terminu
otherwis
unalt
phosphodiest
oligonucleotid
fairli
potent
inhibit
icso
valu
p
could
achiev
poddevin
et
al
approach
avoid
nonspecif
effect
yet
increas
oligonucleotid
stabil
employ
peyman
et
af
screen
array
phosphodiest
oligonucleotid
except
two
phosphorothio
nucleotid
residu
end
antivir
efficaci
cell
cultur
evalu
inhibit
virusinduc
cytopath
effect
cpe
potent
compound
target
translat
start
site
ie
mrna
effect
dose
p
shift
sequenc
reduc
efficaci
ninefold
mismatch
oligonucleotid
inact
p
thu
definit
sequenc
specif
activ
appear
antisens
mediat
howev
attempt
made
evalu
select
inhibit
express
ul
compar
coexpress
anoth
immedi
earli
gene
would
provid
addit
evid
antisens
mechan
activ
numer
ps
oligonucleotid
appar
antisens
sequenc
specif
antihsv
effect
k
field
person
commun
observ
thoroughli
investig
yc
cheng
colleagu
potent
antivir
compound
phosphorothio
dc
p
probabl
inhibit
viru
replic
capac
block
viru
adsorpt
penetr
addit
potent
inhibit
viral
dna
synthesi
gao
et
gao
et
al
dc
compet
templat
dna
polymeras
competit
inhibitor
viral
dna
polymeras
exonucleas
activ
recent
fennewald
colleagu
describ
ps
oligonucleotid
potent
hsv
inhibitor
icso
valu
p
fennewald
et
af
oligonucleotid
compos
entir
dg
dt
residu
effect
block
viru
adsorpt
penetr
although
may
antivir
effect
marek
diseas
viru
mdv
avian
alphaherpesviru
caus
lymphoprolif
diseas
evid
suggest
mainten
tumorigen
state
mdvderiv
lymphoblastoid
cell
line
due
express
gene
famili
kawamura
et
al
evalu
phosphodiest
oligonucleotid
complementari
splice
donor
sequenc
demonstr
sequencespecif
inhibit
express
mrna
inhibit
coloni
growth
soft
agar
multipl
copi
mdv
genom
maintain
lymphoblastoid
cell
appropri
sens
unrel
oligonucleotid
inact
kawamura
et
rel
earli
wellcontrol
studi
provid
direct
evid
transcript
region
requir
tumorigen
mdvtransform
cell
infect
hcmv
often
silent
result
latenc
high
proport
popul
howev
immunocompromis
individu
newborn
hcmv
infect
may
lead
varieti
diseas
syndrom
includ
retin
pharyng
esophag
system
diseas
perhap
coronari
arteri
diseas
speir
et
al
haffey
field
falloon
masur
herp
simplex
viru
replic
cycl
coordin
regul
cascad
immedi
earli
earli
late
transcript
event
howev
wherea
hsv
open
read
frame
hcmv
suggest
complic
replic
pattern
andor
involv
pathogenesi
howev
larger
genom
also
potenti
provid
opportun
antivir
intervent
antisens
oligonucleotid
two
group
research
provid
extens
studi
oligonucleotid
inhibit
hcmv
azad
et
al
survey
seri
oligonucleotid
translat
start
site
code
region
introdexon
region
cap
varieti
gene
includ
dna
polymeras
immedi
earli
gene
ie
ie
azad
et
al
report
potent
oligonucleotid
isi
ps
code
region
ie
accord
author
isi
reduc
ie
hcmv
replic
proportion
valu
pm
fig
although
unrel
oligonucleotid
report
less
activ
reduct
ie
viru
replic
suggest
sequencespecif
antivir
affect
mismatch
isi
substanti
reduc
hybrid
alter
antivir
effect
latter
observ
suggest
antivir
activ
may
due
part
nonantisens
mechan
action
evalu
combin
ganciclovir
foscarnet
isi
addit
antivir
activ
versu
hcmv
azt
also
mainli
addit
inhibit
hiv
azad
et
consid
rel
lack
cytotox
uninfect
cell
isi
consid
author
attract
candid
clinic
evalu
support
isi
clear
slowli
vitreou
fluid
intact
oligonucleotid
accumul
retina
follow
intravitr
inject
rabbit
subacut
intravitr
dose
also
well
toler
monkey
phase
studi
repeat
intravitr
inject
aid
patient
refractori
hcmv
retin
isi
well
toler
dose
pga
calcul
vitreal
concentr
pm
initi
report
state
isi
inhibit
progress
hcmv
retin
patient
progress
diseas
ganciclovir
foscarnet
therapi
isi
expand
clinic
efficaci
studi
anderson
one
virtu
antisens
approach
identifi
novel
antivir
drug
abil
target
larg
array
gene
smith
pari
took
approach
identifi
potent
ps
oligonucleotid
anti
complementari
splice
donor
site
ul
immedi
earli
gene
identifi
essenti
hcmv
dna
origin
replicationdepend
synthesi
pari
et
al
sequenc
specif
antivir
activ
measur
inhibit
viral
dna
replic
establish
comparison
efficaci
ul
anti
effect
express
either
ie
ie
fig
ul
anti
also
reduc
infecti
viru
yield
greater
p
thu
novel
antivir
target
identifi
use
antisens
oligonucleotid
approach
result
potent
select
antivir
agent
futur
clinic
evalu
ul
anti
sequenc
investig
use
chemic
modif
describ
previous
chapter
preclin
evalu
current
ongo
use
hybrid
phosphorothio
nucleotid
also
contain
substitut
two
nucleosid
end
four
nucleosid
end
compound
identifi
gem
fig
combin
potenc
embodi
ul
anti
oligonucleotid
sequenc
enhanc
stabil
hybrid
provid
potenti
system
intravitr
use
initi
entri
clinic
studi
system
therapi
occur
august
aphas
iii
studi
assess
gem
intravitr
treatment
hcmv
retin
approv
studi
underway
epsteinbarr
viru
caus
agent
case
infecti
mononucleosi
acut
infect
associ
activ
viru
replic
ribonucleotid
other
deoxyribonucleotid
nucleotid
phosphorothio
gem
chemic
structur
underlin
base
pagano
epsteinbarr
viru
infect
also
result
latent
infect
result
polyclon
b
cell
lymphoprolif
diseas
immunocompromis
individu
nasopharyng
carcinoma
rel
common
southeast
china
huang
among
gene
express
latenc
reactiv
product
infect
two
subject
design
evalu
antisens
oligonucleotid
epsteinbarr
nuclear
antigen
ebna
gene
requir
mainten
transform
latent
infect
cell
bzlf
gene
requir
reactiv
latent
infect
cell
virusproduct
infect
pagano
pagano
et
al
studi
potenti
unmodifi
ps
antisens
oligonucleotid
inhibitor
ebna
pagano
et
al
oligonucleotid
target
code
region
aug
prolong
treatment
raji
cell
carri
ebv
episom
per
cell
pm
unmodifi
antisens
oligonucleotid
report
result
progress
reduct
ebna
protein
determin
western
blot
ebv
copi
number
determin
southern
blot
similar
treatment
sens
oligonucleotid
control
report
ineffect
roth
et
al
also
use
unmodifi
oligonucleotid
p
complementari
sequenc
ebna
rna
observ
inhibit
ebna
translat
inhibit
cell
prolifer
effect
prolifer
ebvneg
cell
growth
ps
oligonucleotid
use
pagano
doserespons
evalu
growth
inhibit
ebvtransform
cord
blood
b
cell
control
sens
scrambl
sequenc
report
partial
effect
inhibitor
cell
prolifer
antisens
oligonucleotid
report
suppress
growth
total
pm
partial
effect
pm
pagano
et
al
thu
demonstr
viru
infect
ps
oligonucleotid
may
nonspecif
inhibitori
effect
inde
shown
studi
yao
et
al
describ
potent
inhibit
ecgo
p
ebv
yield
cell
chronic
infect
highproduc
cell
line
use
ps
without
sequenc
specif
ebv
target
mechan
inhibit
may
result
block
dna
synthesi
also
describ
previous
antihsv
nonspecif
oligonucleotid
efficaci
sequencespecif
targetspecif
antisens
inhibit
bzlf
express
describ
daibata
et
al
cellular
dna
synthesi
express
b
cell
membran
protein
appar
similar
inhibit
viru
product
observ
cell
ebv
produc
cell
line
albeit
prolong
antisens
treatment
thu
criteria
sequenc
gene
target
specif
oligonucleotid
design
inhibit
express
bzlf
gene
inhibit
viru
replic
probabl
function
antisens
mechan
although
nonspecif
effect
may
also
occur
fig
tabl
influenza
virus
envelop
virion
segment
singlestrand
rna
genom
caus
agent
epidem
acut
respiratori
sens
sequenc
complementari
antisens
revers
sequenc
ident
nucleotid
sequenc
antisens
read
opposit
direct
ill
sever
diseas
negativestrand
rna
genom
influenza
b
virus
contain
eight
segment
act
templat
viral
mrna
synthesi
well
synthesi
antigenom
positivestrand
rna
intermedi
lamb
webster
negativestrand
genom
packag
virion
along
rnadepend
rna
polymeras
viral
replic
complex
process
viral
mrna
synthesi
replic
occur
nucleu
infect
cell
mrna
synthesi
initi
host
cellderiv
primer
contain
cap
rna
fragment
cellular
rna
polymeras
transcript
four
viral
protein
requir
mrna
synthesi
np
major
structur
protein
nucleocapsid
pa
protein
polymeras
protein
protein
encod
separ
segment
viral
genom
lamb
webster
attract
target
antivir
inhibit
current
antivir
therapi
influenza
includ
amantidin
rimantidin
act
block
ion
channel
form
protein
ion
channel
ph
activ
requir
uncoat
viral
nucleocapsid
viru
infect
amantidin
rimantidin
partial
effect
especi
given
prophylact
drug
resist
viru
variant
readili
aris
belsh
et
recent
specif
inhibitor
viral
neuraminidas
activ
requir
viru
bind
cell
design
although
approach
appear
promis
addit
therapi
requir
annual
immun
also
effect
highrisk
popul
howev
longterm
immun
possibl
due
antigen
variat
epidem
season
season
oligonucleotid
effect
antiinfluenza
agent
cell
cultur
assay
phosphorothio
oligonucleotid
target
viral
rna
mrna
gene
inhibit
replic
influenza
influenza
c
virus
leiter
et
al
influenza
c
viru
ps
oligonucleotid
target
viral
rna
gene
inhibit
plaqu
format
pm
caus
reduct
infecti
viru
pm
control
oligonucleotid
contain
one
mismatch
much
less
activ
inhibit
plaqu
format
pm
oligonucleotid
contain
three
mismatch
lack
influenza
sequenc
inhibit
plaqu
format
pm
although
sequencespecif
effect
observ
activ
oligonucleotid
contain
g
quartet
mismatch
elimin
motif
known
whether
g
quartet
contribut
addit
nonantisens
mechan
anoth
studi
employ
phosphodiest
oligonucleotid
modifi
end
hydrophob
group
nundecanol
kabanov
et
al
modifi
target
polymeras
gene
report
inhibit
influenza
plaqu
format
pm
wherea
unmodifi
modifi
nonsens
ineffect
mechan
inhibit
although
appar
sequenc
specif
elabor
import
sinc
addit
potenti
antisens
inhibit
oligonucleotid
also
use
inhibitor
influenza
viru
rna
polymeras
vitro
chung
et
al
short
oligonucleotid
contain
cap
structur
bind
vitro
viral
polymeras
high
affin
inhibit
capdepend
transcript
antivir
effect
oligonucleotid
measur
clearli
sequencespecif
inhibit
influenza
viru
replic
well
document
whether
antivir
activ
result
sole
antisens
mechan
action
includ
unrel
inhibit
polymeras
adsorptiodpenetr
combin
effect
entir
clear
respiratori
syncyti
viru
rsv
caus
sever
lower
respiratori
tract
diseas
infant
young
children
immunocompromis
adult
collin
et
al
respiratori
syncyti
viru
envelop
viru
contain
unseg
negativestrand
genom
approxim
nucleotid
collin
et
al
genom
encod
viral
protein
translat
individu
mrna
rna
transcrib
negativestrand
genom
viral
polymeras
complex
n
p
l
protein
addit
complex
replic
negativestrand
genom
positivestrand
intermedi
insert
progeni
virion
replic
occur
cytoplasm
infect
cell
current
ribavirin
use
therapeut
rsv
diseas
groothui
levin
ribavirin
believ
inhibit
rsv
replic
sever
potenti
mechan
inhibit
viral
polymeras
inhibit
cap
format
mrna
inhibit
imp
dehydrogenas
decreas
intracellular
gtp
level
gilbert
knight
domin
mechan
antivir
activ
uncertain
unfortun
clinic
benefit
ribavirin
small
occur
portion
rsvinfect
individu
levin
clearli
remain
need
develop
effect
therapeut
rsv
diseas
oligodeoxyribonucleotid
target
genom
rna
inhibit
rsv
replic
cell
cultur
appar
antisens
mechan
cell
infect
rsv
strain
presenc
oligonucleotid
replic
measur
enzym
immunosorb
assay
elisa
viru
yield
assay
jairath
et
al
use
elisa
ecso
valu
pm
antisens
oligonucleotid
target
start
gene
assay
antisens
oligonucleotid
potent
control
oligonucleotid
contain
revers
sequenc
oligonucleotid
target
rsv
mrna
random
sequenc
oligonucleotid
ribavirin
tabl
importantli
sequencespecif
deplet
genom
target
follow
treatment
cell
antisens
oligonucleotid
demonstr
revers
transcriptasepolymeras
chain
reaction
rtpcr
fig
specif
cleavag
genom
target
rna
detect
antisens
oligonucleotidebind
site
suggest
cellular
rnase
h
particip
reaction
observ
provid
situ
quantit
genom
rsv
rna
rsv
cdna
prepar
revers
transcript
pcr
conduct
use
primer
gener
pair
product
rsv
cdna
serial
dilut
competit
plasmid
templat
gener
pair
product
primer
includ
constant
amount
rsv
cdna
determin
concentr
rsv
rna
present
oligonucleotid
treatment
cell
treat
scrambl
control
oligonucleotid
contain
measur
rsv
cdna
pcr
product
cell
treat
antisens
oligonucleotid
rsv
cdna
pcr
product
detect
reprint
antivir
re
jairath
brown
evid
oligonucleotid
design
bind
target
genom
rna
trigger
cleavag
heteroduplex
precis
hope
antisens
mechan
action
howev
antisens
oligonucleotid
contain
quartet
system
four
consecut
guanyl
acid
residu
contribut
nonantisens
sequencespecif
inhibit
virus
cellular
function
wyatt
etal
burgess
etal
rsv
antisens
oligonucleotid
fourfold
activ
oligonucleotid
contain
gs
includ
control
revers
sequenc
tabl
suggest
four
gs
may
contribut
significantli
antivir
activ
oligonucleotid
predomin
antivir
factor
thu
antisens
oligonucleotid
target
rsv
genom
rna
effect
inhibit
rsv
replic
may
therapeut
valu
hepat
b
viru
hbv
member
hepadnaviru
famili
also
includ
hepat
virus
pekin
duck
heron
woodchuck
ground
squirrel
worldwid
million
peopl
infect
hbv
caus
acut
selflimit
chronic
infect
liver
infect
individu
acut
infect
character
appear
neutral
antibodi
chronic
infect
individu
continu
shed
viru
blood
epidemiolog
studi
link
chronic
infect
hepatocellular
carcinoma
interferon
use
treat
chronic
hepat
partial
success
suppress
viru
shed
provid
elimin
chronic
infect
locarnini
cunningham
potenti
therapeut
lamivudin
clinic
evalu
dienstag
et
al
need
addit
option
therapi
provid
impetu
identifi
novel
inhibitor
novel
target
hepat
b
viru
compact
dna
viru
kb
contain
four
open
read
frame
encod
three
envelop
surfac
antigen
two
nucleocapsid
hbcag
hbeag
protein
polymeras
p
gene
product
x
gene
product
genom
transcrib
produc
two
predomin
transcript
kb
two
minor
transcript
kb
addit
open
read
frame
hbv
contain
novel
genet
target
oligonucleotid
encapsid
signal
short
base
rna
sequenc
welldefin
secondari
structur
sequenc
repeat
end
pregenom
rna
recogn
viral
protein
packag
viral
rna
nucleocapsid
also
revers
transcript
initi
sequenc
within
encapsid
signal
hbv
rna
region
dri
drii
recogn
hbv
polymeras
requir
transloc
enzym
revers
transcript
complex
natur
hbv
genom
replic
provid
opportun
identifi
antisens
oligonucleotid
antihbv
activ
sever
group
report
inhibit
target
translat
hbv
structur
protein
goodarzi
et
al
blum
et
al
seri
oligonucleotid
hbv
evalu
use
hepatocellular
carcinomaderiv
cell
line
stabli
transfect
hbv
dna
korba
gerin
oligonucleotid
report
inhibit
hbv
virion
product
sequencespecif
fashion
oligonucleotid
target
transcript
encod
structur
protein
gene
c
gene
hbv
virion
inhibit
reportedli
correl
well
inhibit
protein
product
antigen
inhibit
also
report
sequenc
specif
exampl
oligonucleotid
target
gene
inhibit
hbsag
product
effect
hbeag
hbcag
level
interestingli
oligonucleotid
target
encapsid
sequenc
report
among
potent
inhibitor
identifi
experi
oligonucleotid
inhibit
virion
product
intracellular
hbv
dna
replic
consist
requir
region
packag
viral
rna
viral
dna
replic
none
oligonucleotid
decreas
level
hbv
rna
speci
suggest
rnase
h
contribut
antivir
activ
assay
system
differ
studi
phosphorothio
oligonucleotid
target
duck
hepat
b
viru
pre
gene
inhibit
viru
replic
vivo
offensperg
et
oligonucleotid
activ
sever
oligonucleotid
evalu
cell
cultur
vivo
viru
replic
measur
presenc
viral
dna
replic
intermedi
liver
well
presenc
viral
antigen
surfac
antigen
core
antigen
liver
zn
vivo
inhibit
determin
dose
depend
sequenc
specif
dose
mglkg
day
caus
mark
decreas
hbv
dna
replic
reduct
viral
antigen
serum
liver
mdkg
littl
effect
hbv
dna
antigen
sens
random
oligonucleotid
inhibit
viru
product
import
result
repres
first
observ
antisens
oligonucleotid
inhibit
viru
infect
vivo
fig
hbv
x
protein
hbx
transactiv
also
report
target
success
antisens
oligonucleotid
vivo
moriya
et
al
lane
per
gram
bodi
weight
lane
sampl
untreat
control
duck
offensperg
et
al
offensperg
et
al
transgen
mice
express
hbx
develop
liver
lesion
age
month
liver
tumor
month
accord
author
treat
ps
oligonucleotid
target
hbx
translat
start
site
intraperiton
week
hbx
product
inhibit
measur
rna
protein
product
addit
hepat
lesion
reduc
inhibit
report
sequenc
specif
sens
control
inhibit
also
oligonucleotid
target
within
hbx
code
region
inact
subject
futur
posit
studi
hbx
therefor
appear
potenti
use
target
hbv
treatment
liver
diseas
may
enhanc
target
oligonucleotid
hepatocyt
host
cell
hepat
viru
replic
two
studi
oligonucleotid
conjug
asialoorosmucoid
report
taken
cell
contain
asialoglycoprotein
receptor
wu
wu
bunnel
et
al
conjug
reportedli
attain
greater
cell
associ
unconjug
oligonucleotid
increas
uptak
depend
presenc
asialoglycoprotein
receptor
studi
report
increas
uptak
result
antisens
inhibit
target
gene
antisens
oligonucleotid
complex
specif
decreas
product
hbv
antigen
medium
cell
random
oligonucleotid
effect
viru
product
report
uncomplex
antisens
oligonucleotid
reduc
hbv
antigen
product
contrast
observ
korba
gerin
describ
uncomplex
phosphorothio
effect
inhibitor
hbv
replic
korba
gerin
differ
result
may
due
oligonucleotid
sequenc
use
investig
result
especi
vivo
studi
duck
hepat
viru
show
antisens
oligonucleotid
provid
effect
therapi
hepat
b
infect
phosphorothio
oligonucleotid
readili
attain
high
concentr
liver
agraw
temsamani
opportun
target
hepatocyt
antisens
oligonucleotid
may
provid
uniqu
advantag
therapi
human
papillomavirus
hpv
includ
least
type
base
dna
sequenc
divers
measur
liquid
hybrid
infect
epitheli
cell
mucocutan
surfac
result
lesion
benign
wart
cervic
carcinoma
viru
type
specif
anatom
site
replic
sever
hpv
type
infect
genit
epithelia
repres
preval
etiolog
agent
sexual
transmit
viral
diseas
genit
hpv
type
subdivid
highrisk
type
associ
develop
neoplasm
commonli
lowrisk
type
rare
associ
malign
commonli
shah
howley
genom
hpv
type
circular
doublestrand
dna
approxim
base
pair
genom
divid
three
distinct
function
domain
upstream
regulatori
region
contain
origin
viral
dna
replic
plu
enhanc
promot
involv
transcript
e
region
encod
gene
requir
veget
function
l
region
encod
structur
protein
polypeptid
express
e
region
sever
function
e
l
requir
episom
dna
replic
control
transcript
also
may
involv
initi
dna
replic
interact
cytokeratin
involv
cell
transform
viral
protein
translat
famili
altern
splice
mrna
howley
current
therapi
treat
hpv
infect
involv
excis
destruct
infect
tissu
rather
inhibit
revers
viral
direct
tumorigenesi
even
though
viral
replic
transform
reason
well
understood
use
knowledg
identifi
select
new
antivir
drug
lack
situat
provid
rich
opportun
ration
design
antisens
antisens
oligonucleotid
design
inhibit
viral
replic
inhibit
cellular
transform
evalu
one
compound
isi
target
hpv
mrna
translat
initi
region
cowsert
et
al
report
cell
cultur
studi
use
bovin
papillomaviru
bpv
model
system
show
oligonucleotid
target
could
inhibit
transactiv
transient
assay
bpvinduc
transform
cell
focu
format
suggest
gene
appropri
target
antivir
therapi
hpv
replic
cell
cultur
studi
use
second
model
system
transactiv
report
gene
chloramphenicol
acetyltransferas
measur
isi
report
inhibit
report
express
ecso
approxim
pm
fig
inhibit
said
sequenc
specif
control
oligonucleotid
target
bpv
translat
start
site
reportedli
inhibit
concentr
pm
studi
led
phase
clinic
trial
treatment
genit
wart
isi
howev
trial
discontinu
sponsor
isi
pharmaceut
carlsbad
ca
combin
effort
hybridon
cambridg
roch
research
center
welwyngarden
citi
uk
result
identif
sequencespecif
gene
targetspecif
antisens
oligonucleotid
activ
cell
cultur
assay
mous
xenograft
model
human
papillomaviru
replic
lewi
et
al
antisens
ps
oligonucleotid
target
hpv
type
e
l
gene
select
reduc
e
l
mrna
level
cell
cultur
modifi
version
sequenc
contain
nucleosid
addit
ps
backbon
significantli
reduc
growth
hpvinfect
cyst
mice
mi
drug
concentr
pm
figur
inhibit
transactiv
antisens
oligonucleotid
isi
chloramphenicol
acetyltransferas
cat
express
plasmid
vector
contain
sequenc
use
measur
transactiv
cell
treat
oligonucleotid
transfect
express
construct
cat
express
report
analysi
varianc
acetyl
chloramphenicol
perform
four
separ
experi
control
oligonucleotid
isi
inhibit
cat
express
cowsert
et
al
match
control
oligonucleotid
decreas
cyst
growth
histolog
antisens
oligonucleotidetr
cyst
carri
fewer
koilocyt
suggest
antisens
treatment
decreas
viral
load
find
explor
potenti
develop
antisens
oligonucleotid
therapi
genit
wart
sever
studi
gene
respons
cellular
transform
target
antisens
oligonucleotid
studi
use
cervic
carcinomaderiv
cell
line
contain
hpv
andor
measur
growth
inhibit
assess
antisens
oligonucleotid
activ
earli
experi
plasmid
express
hpv
antisens
rna
andor
alter
growth
characterist
hela
cell
steel
et
al
antisens
express
regul
induc
mous
mammari
tumor
viru
mmtv
promot
induct
result
slow
growth
rate
decreas
growth
soft
agar
increas
serum
requir
vero
cell
contain
hpv
sequenc
effect
transfect
antisens
plasmid
also
plasmid
express
sens
construct
chang
growth
characterist
hela
cell
characterist
suggest
express
antisens
rna
caus
decreas
andor
express
alter
transform
phenotyp
hela
cell
similarli
hpvspecif
ps
oligonucleotid
inhibit
caski
cell
growth
depend
hpv
express
much
concentr
pm
storey
et
id
effect
appar
sequenc
specif
sinc
two
oligonucleotid
target
overlap
translat
start
site
hpv
hpv
effect
six
hpvspecif
oligonucleotid
target
region
gene
well
random
sequenc
oligonucleotid
inhibit
growth
howev
signific
decreas
hpv
mrna
protein
suggest
mechan
inhibit
although
select
antisens
subsequ
studi
use
ps
oligonucleotid
target
similar
region
show
appar
antisens
effect
tan
ting
experi
oligonucleotid
deliv
cell
cation
lipid
cell
growth
express
reportedli
specif
inhibit
antisens
target
rna
interestingli
report
also
suggest
express
also
inhibit
antisens
oligonucleotid
possibl
due
inhibit
bicistron
transcript
antisens
oligonucleotid
also
report
inhibit
tumor
growth
siha
cell
nude
mice
addit
report
decreas
express
measur
tumor
effect
control
gene
actin
control
oligonucleotid
contain
random
sequenc
report
inhibit
tumor
growth
express
vivo
result
suggest
inhibit
may
effect
treatment
hpvinduc
tumor
picornavirus
nonenvelop
virus
contain
singl
positivestrand
rna
genom
virus
compris
larg
famili
human
agricultur
pathogen
includ
polioviru
hepat
viru
foot
mouth
diseas
viru
fmdv
translat
picornaviru
rna
occur
novel
capindepend
mechan
involv
initi
intern
site
viral
rna
specif
recogn
ribosom
cellular
protein
sever
virus
target
antisens
oligonucleotid
inhibit
studi
demonstr
versatil
antisens
approach
encephalomyocard
viru
emcv
use
model
system
studi
translat
initi
intern
ribosom
entri
jang
et
al
jang
et
al
antisens
phosphodiest
oligonucleotid
target
untransl
region
translat
start
site
emcv
inhibit
cellfre
translat
rabbit
reticulocyt
lysat
sankar
et
al
specif
demonstr
show
oligonucleotid
contain
singl
mismatch
inhibit
translat
import
untransl
region
confirm
oligonucleotid
target
code
region
end
genom
inhibit
translat
although
viral
replic
assay
perform
result
cellfre
translat
system
suggest
inhibit
intern
ribosom
entri
oligonucleotid
provid
novel
target
viru
inhibit
antisens
oligonucleotid
inhibit
replic
fmdv
guticrrez
et
al
high
concentr
p
phosphodiest
oligonucleotid
microinject
uninfect
cell
infect
fmdv
modest
reduct
percentag
cell
express
fmdv
antigen
detect
hr
infect
sequenc
specif
observ
sinc
scrambl
control
oligonucleotid
ineffect
studi
follow
fate
fluoresceinlabel
oligonucleotid
indic
local
nucleu
microinject
high
concentr
appar
satur
transport
process
oligonucleotid
detect
cytoplasm
site
viral
replic
phosphorothio
version
oligonucleotid
sequenc
inhibit
infecti
viru
yield
use
high
concentr
pm
effect
appear
sequenc
specif
sinc
scrambl
control
ineffect
howev
modest
effect
seen
studi
use
high
oligonucleotid
concentr
suggest
util
antisens
oligonucleotid
fmdv
probabl
quit
limit
coronavirus
larg
envelop
virion
contain
positivestrand
rna
genom
human
strain
respons
acut
respiratori
diseas
mous
hepat
viru
mhv
caus
respiratori
gastrointestin
infect
well
hepat
use
model
system
studi
coronaviru
replic
viral
rnadepend
rna
polymeras
synthes
fulllength
negativesens
copi
genom
prior
copi
seri
subgenom
mrna
neg
strand
subgenom
mrna
contain
end
common
leader
sequenc
deriv
end
genom
subgenom
rna
deriv
discontinu
rna
synthesi
leader
antisens
oligonucleotid
complementari
leader
sequenc
report
inhibit
mhv
plaqu
format
oligonucleotid
present
infect
mizutani
et
al
addit
viral
rna
decreas
effect
report
sequenc
specif
select
sens
oligonucleotid
inhibit
viru
replic
cellular
rna
effect
antisens
oligonucleotid
flavivirida
consist
three
group
flavivirus
pestivirus
hepat
c
wide
varieti
arthropodborn
viru
infect
human
caus
flavivirus
result
sever
diseas
enceph
high
fever
hemorrhag
fever
virion
flavivirus
envelop
encapsid
positivestrand
rna
genom
translat
singl
polyprotein
polyprotein
process
cellular
viral
proteas
produc
matur
protein
contain
similar
function
organ
structur
protein
n
terminu
nonstructur
protein
c
terminu
rice
dengu
viru
group
contain
four
distinct
serotyp
caus
debilit
nonfat
fever
sever
diseas
dengu
hemorrhag
fever
result
reinfect
heterolog
serotyp
presum
caus
antibodymedi
enhanc
viru
replic
monocyt
cell
phenomenon
vaccin
approach
unsuccess
may
especi
difficult
protect
four
serotyp
monath
antisens
oligonucleotid
target
translat
initi
region
also
untransl
region
report
effect
inhibitor
dengu
viru
type
replic
raviprakash
et
al
specif
modif
posit
uridin
cytosin
propynyl
group
requir
sequencespecif
inhibit
viral
antigen
product
observ
concentr
less
equal
pm
phosphodiest
ps
oligonucleotid
report
inhibit
sequencespecif
fashion
interestingli
inhibit
detect
microinject
oligonucleotid
suggest
effect
present
propynylmodifi
compound
intact
cell
may
problemat
hepat
c
viru
hcv
positivestrand
rna
viru
also
infect
hepatocyt
caus
acut
chronic
hepat
hepat
c
viru
major
caus
nona
nonb
hepat
like
hbv
associ
hepatocellular
carcinoma
organ
hcv
genom
similar
pestivirus
flavivirus
structur
protein
end
nonstructur
protein
end
houghton
viru
encod
singl
polyprotein
process
viral
cellular
proteas
hepat
c
viru
also
contain
short
untransl
region
utr
utr
repres
highli
conserv
region
viru
bukh
et
al
utr
region
facilit
intern
ribosom
entri
translat
occur
ribosom
scan
rna
cap
instead
ribosom
bind
intern
secondari
structur
form
utr
wang
et
al
addit
separ
experi
shown
hcv
utr
sequenc
control
translat
downstream
sequenc
et
al
conserv
natur
sequenc
requir
translat
suggest
utr
potenti
provid
excel
target
antisens
oligonucleotid
antivir
agent
hepat
c
viru
recent
suggest
replic
cell
cultur
et
al
viru
replic
hepatoma
cell
line
detect
presenc
positiveand
negativestrand
rna
rtpcr
presenc
viru
antigen
report
although
infect
model
may
potenti
futur
avail
antivir
studi
howev
oligonucleotid
evalu
inhibitor
hcv
replic
lymphocyt
cell
line
mizutani
et
al
sequencespecif
inhibit
measur
presenc
absenc
hcv
rna
cell
although
quantit
rna
direct
evid
rna
replic
present
limit
data
provid
confid
viru
replic
inhibit
cellbas
assay
system
go
provid
model
hcv
infect
limit
viru
replic
system
novel
model
system
evalu
antisens
oligonucleotid
develop
vitro
translat
rna
contain
hcv
utr
sequenc
use
screen
oligonucleotid
wakita
wand
sequencespecif
oligonucleotid
identifi
report
inhibit
translat
artifici
system
oligonucleotid
near
translat
start
site
activ
assay
domain
utr
contain
oligonucleotidesensit
sequenc
also
identifi
assay
system
oligonucleotid
transfect
cell
along
plasmid
express
hcv
utr
fuse
report
gene
luciferas
alt
et
al
control
luciferas
express
compar
product
unrel
gene
hepat
b
surfac
antigen
transfect
separ
plasmid
sequencespecif
inhibit
report
oligonucleotid
target
near
translat
start
site
also
utr
sever
oligonucleotid
target
core
proteincod
sequenc
also
inhibit
protein
product
alt
et
al
hepat
c
viru
gene
express
report
inhibit
stabli
transfect
hepatocyt
activ
oligonucleotid
target
sequenc
untransl
region
reinforc
import
region
regul
hcv
express
hanecak
et
al
phosphorothio
oligonucleotid
report
inhibit
rna
protein
product
sequencespecif
lengthdepend
fashion
interestingli
oligonucleotid
residu
report
inhibit
protein
product
without
effect
hcv
rna
similar
studi
sequencespecif
interact
oligonucleotid
hcv
utr
report
cell
stabli
transfect
hcv
base
p
brown
varga
h
hamlin
b
frank
walther
k
field
r
e
kilkuski
unpublish
observ
cell
express
hcv
c
e
l
protein
translat
control
utr
treat
individu
oligonucleotid
presenc
cation
lipid
hcv
rna
cleavag
detect
use
ribonucleas
protect
assay
cleavag
map
oligonucleotidebind
site
cleavag
requir
rnase
h
sinc
treatment
oligonucleotid
contain
residu
result
rna
cleavag
importantli
result
suggest
ps
oligonucleotid
act
antisens
mechan
specif
interact
target
ribonucleotid
sequenc
rhabdovirus
widespread
famili
includ
rabi
viru
vesicular
stomat
viru
vsv
wellstudi
member
rhabdoviru
famili
caus
flulik
symptom
infect
human
vesicular
stomat
viru
envelop
viru
contain
five
protein
negativestrand
genom
five
individu
messeng
rna
transcrib
genom
novel
modif
oligonucleotid
evalu
antivsv
agent
psoralenmodifi
methyl
phosphon
oligonucleotid
report
bind
specif
vsv
mrna
ilz
vitro
specif
crosslink
occur
oligonucleotid
target
n
mrna
shorter
oligonucleotid
design
bind
specif
mrna
also
report
bind
n
mrna
oligonucleotid
partial
complementari
residu
n
mrna
n
mrna
predomin
rna
speci
mixtur
high
degre
homolog
differ
mrna
vsv
make
specif
oligonucleotid
target
difficult
howev
abil
target
one
rna
oligonucleotid
could
potenti
improv
potenc
antivir
compound
antivir
activ
psoralenmodifi
oligonucleotid
report
separ
studi
oligonucleotid
conjug
end
polyllysin
reportedli
inhibit
vsv
antigen
synthesi
viru
yield
lemaitr
et
al
conjug
oligonucleotid
complementari
end
vsv
n
mrna
reportedli
inhibit
viru
product
nm
specif
suggest
lack
effect
replic
control
viru
encephalomyocard
viru
condit
also
second
conjug
oligonucleotid
target
code
sequenc
n
mrna
effect
viru
yield
unconjug
oligonucleotid
evalu
effect
polylysin
deliveri
could
address
directli
second
approach
develop
effect
antisens
antivir
agent
situ
transcript
antisens
rna
select
blockad
viru
replic
antisens
rna
use
defin
activ
gene
product
observ
phenotyp
effect
select
inhibit
translat
approach
use
help
defin
role
human
papillomavirusencod
transcript
cervic
carcinoma
cell
von
knebel
doeberitz
gissmann
demonstr
express
antisens
rna
follow
transfect
hpvtransform
cell
reduc
number
surviv
cell
capabl
coloni
format
von
knebel
doeberitz
gissmann
similar
transfect
vector
express
sens
rna
alter
coloni
format
transfect
antisens
rna
vector
control
cell
carri
hpv
effect
cell
growth
express
antisens
rna
success
inhibit
mous
hepat
viru
mizutani
et
al
thiering
et
al
parvoviru
ramirez
et
al
polyoma
viru
liu
et
al
simian
immunodefici
viru
tung
human
lymphotrop
viru
type
fujita
shiku
measl
viru
koschel
et
af
antisens
rna
studi
result
viru
inhibit
readili
interpret
result
leiter
et
al
demonstr
even
success
inhibit
influenza
replic
cell
express
virusspecif
rna
vector
inhibit
probabl
result
induct
interferon
follow
format
doublestrand
rna
hybrid
sens
antisens
strand
leiter
et
al
doublestrand
rna
repeatedli
confirm
potent
induc
interferon
primari
mechan
interferon
induc
viru
infect
marcu
studi
induct
interferon
check
leav
suspect
direct
role
antisens
mechan
antivir
activ
result
vectorexpress
antisens
rna
thu
emphas
need
extens
control
studi
hiv
sever
approach
fig
taken
inhibit
replic
rna
express
transfect
cell
transcrib
antisens
rna
transactiv
respons
tar
element
chuah
et
al
gag
region
sczakiel
pawlita
tat
rev
region
junker
et
al
sczakiel
et
al
leader
region
hiv
sun
et
af
confer
variou
degre
protect
hiv
challeng
infect
cell
cultur
addit
nonantisens
approach
overexpress
tar
rev
respons
element
rre
decoy
provid
mean
inactiv
tat
rev
protein
altern
bind
antivir
decoy
approach
success
demonstr
bevec
et
af
lori
et
af
singl
vector
chang
et
af
combin
use
tar
decoy
vectorexpress
antisens
rna
tat
mrna
block
activ
tat
protein
block
translat
compar
vector
control
combin
decoy
antisens
approach
inhibit
tat
activ
combin
rna
decoy
antisens
rna
taken
step
construct
vector
express
polymer
tar
decoy
antisens
tat
refer
avenu
ex
vivo
gene
therapi
provid
compet
expand
pool
cell
lisziewicz
et
al
ribozym
catalyt
rna
theoret
combin
specif
antisens
molecul
bind
complementari
rna
target
catalyt
core
combin
provid
potent
select
antivir
agent
express
ribozym
undergo
evalu
refin
mani
laboratori
sarver
et
al
first
demonstr
use
express
hammerhead
ribozym
target
gag
sequenc
hiv
increas
resist
hela
cell
hiv
infect
sarver
et
al
sinc
numer
public
use
express
hammerhead
hairpin
ribozym
appear
first
clinic
trial
aid
patient
soon
hand
leavitt
et
al
review
antivir
ribozym
literatur
see
kijima
et
al
howev
purpos
chapter
highlight
certain
key
studi
wongstaal
colleagu
concentr
develop
potent
activ
hairpin
ribozym
inhibit
hiv
replic
peripher
blood
lymphocyt
mononuclear
cell
deriv
hematopoiet
stem
cell
leavitt
et
al
yamada
et
al
b
yu
et
al
target
ribozym
either
leader
sequenc
conserv
region
pol
gene
express
retrovir
vector
hammerhead
ribozym
util
numer
investig
homann
et
al
crisel
et
al
sun
et
al
lo
et
al
target
tat
gene
ltwgag
region
specif
requir
catalyt
activ
obtain
optim
antihiv
activ
suggest
ribozym
function
catalyt
manner
mere
antisens
mechan
action
aim
chapter
increas
awar
opportun
advanc
antisensegen
therapi
technolog
mean
identifi
novel
antivir
gene
target
identifi
molecul
attract
therapeut
potenti
use
antisens
oligonucleotid
antisens
rna
novel
antivir
target
report
hcmv
hiv
hepat
virus
other
mani
case
provid
proof
principl
need
launch
concert
effort
seriou
antivir
drug
discoveri
develop
addit
technolog
alreadi
yield
antivir
drug
candid
antisens
clinic
trial
ongo
hiv
hcmv
other
preclin
stage
develop
parallel
antisens
decoy
ribozym
gene
therapi
approach
also
gain
credibl
potenti
attract
mean
enhanc
cellular
resist
hiv
infect
lead
belief
success
one
antisens
therapeut
approach
undergo
evalu
clinic
result
acceler
momentum
toward
develop
array
effect
antisens
therapeut
oligonucleotid
virus
heretofor
unassail
convent
therapi
vulner
antisens
approach
like
evolv
field
specif
antisens
mechan
action
nonspecif
activ
precis
defin
appreci
contribut
overal
antivir
efficaci
parallel
identif
novel
chemic
modif
oligonucleotid
provid
attract
pharmacolog
properti
next
gener
oligonucleotid
drug
emerg
end
result
identif
antisens
oligonucleotid
fulfil
promis
antisensepot
activ
antivir
agent
demonstr
high
select
viral
target
virtu
sequenc
complementar
antisens
hybrid
antisens
rna
rna
decoy
express
ribozym
problem
differ
issu
concern
control
express
appropri
cell
consequ
emphasi
induc
vector
construct
cell
target
rna
stabil
key
practic
applic
littl
doubt
regardless
outcom
present
effort
show
clinic
efficaci
field
genet
pharmacolog
score
impress
gain
progress
field
gain
momentum
momentum
introduc
new
paradigm
antivir
target
identif
antivir
drug
discoveri
